
Karin Jordan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2815967/publications.pdf Version: 2024-02-01



KADIN LODOAN

#	Article	IF	CITATIONS
1	Comparative activity of antiemetic drugs. Critical Reviews in Oncology/Hematology, 2007, 61, 162-175.	4.4	88
2	Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. Supportive Care in Cancer, 2011, 19, 5-14.	2.2	84
3	2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy. Supportive Care in Cancer, 2017, 25, 289-294.	2.2	54
4	Efficacy of the neurokininâ€1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatinâ€based chemotherapy. Cancer, 2016, 122, 2418-2425.	4.1	48
5	Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009. Supportive Care in Cancer, 2011, 19, 37-42.	2.2	46
6	2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. Supportive Care in Cancer, 2017, 25, 271-275.	2.2	36
7	Radiation induced nausea and vomiting. European Journal of Pharmacology, 2014, 722, 165-171.	3.5	32
8	2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting. Supportive Care in Cancer, 2017, 25, 309-316.	2.2	30
9	Phase II Trial of Capecitabine/Irinotecan and Capecitabine/Oxaliplatin in Advanced Gastrointestinal Cancers. Clinical Colorectal Cancer, 2004, 4, 46-50.	2.3	27
10	Prophylactic Management of Radiation-Induced Nausea and Vomiting. BioMed Research International, 2015, 2015, 1-8.	1.9	21
11	Trans sectoral care of geriatric cancer patients based on comprehensive geriatric assessment and patient-reported quality of life - Results of a multicenter study to develop and pilot test a patient-centered interdisciplinary care concept for geriatric oncology patients (PIVOG). Journal of Geriatric Oncology, 2017, 8, 262-270.	1.0	20
12	Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens. Supportive Care in Cancer, 2016, 24, 4617-4625.	2.2	18
13	Trabectedin: Supportive care strategies and safety profile. Critical Reviews in Oncology/Hematology, 2015, 94, 279-290.	4.4	15
14	Neurokinin-1-Receptor Antagonists: A New Approach in Antiemetic Therapy. Oncology Research and Treatment, 2006, 29, 39-43.	1.2	12
15	Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1101-1107.	0.8	12
16	PRO-ONKO—selection of patient-reported outcome assessments for the clinical use in cancer patients—a mixed-method multicenter cross-sectional exploratory study. Supportive Care in Cancer, 2016, 24, 2503-2512.	2.2	11
17	Thymic pathologies in myasthenia gravis: a preoperative assessment of CAT scan and nuclear based imaging. Journal of Neurology, 2016, 263, 641-648.	3.6	11
18	Antiemetic Efficacy of an Oral Suspension of Granisetron plus Dexamethasone and Influence of Quality of Life on Risk for Nausea and Vomiting. Oncology Research and Treatment, 2005, 28, 88-92.	1.2	7

Karin Jordan

#	Article	IF	CITATIONS
19	Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial. Supportive Care in Cancer, 2018, 26, 3773-3780.	2.2	6
20	Diagnostic work-up for the detection of malnutrition in hospitalized cancer patients. Journal of Community and Supportive Oncology, 2016, 14, 155-161.	0.1	4
21	Successful use of an immune checkpoint inhibitor in a patient with myasthenia gravis in remission. Muscle and Nerve, 2019, 60, E7-E8.	2.2	3
22	NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting (CINV) following repeated chemotherapy cycles: Results of a phase III trial Journal of Clinical Oncology, 2013, 31, e20716-e20716.	1.6	1
23	A randomized double-blind phase III pivotal study of febuxostat (FEB) versus allopurinol (ALL) in the prevention of tumor lysis syndrome (TLS): Florence study Journal of Clinical Oncology, 2014, 32, 9641-9641.	1.6	Ο
24	Management of primary intraocular lymphoma (PIOL): Results from the prospective German PIOL registry (PIOL-R) Journal of Clinical Oncology, 2014, 32, 2056-2056.	1.6	0